Pancragen

Pancragen is a naturally occurring tetrapeptide bioregulator primarily targeting the pancreas. It has been shown to help regulate blood sugar levels, enhance pancreatic endocrine function, modulate melatonin expression, and mitigate the incidence and severity of metabolic syndrome.

Pancragen’s potential applications extend to the treatment of diabetes and the metabolic effects of aging, positioning it as an anti-aging peptide for the pancreas. Its amino acid sequence, Lys-Glu-Asp-Trp (KEDW), is crucial for its biological activity. Research indicates that Pancragen stimulates the expression of differentiation factors in pancreatic cells, promoting the growth of acinar and islet of Langerhans cells, which are responsible for insulin and glucagon production.

Additionally, Pancragen has been found to normalize insulin secretion, reduce glucose levels, and decrease insulin resistance, suggesting a direct impact on melatonin signaling. This is significant because disruptions in melatonin signaling are linked to the development of type 2 diabetes and metabolic syndrome. Furthermore, Pancragen’s ability to increase the expression of matrix metalloproteinases and anti-apoptotic proteins while decreasing pro-apoptotic proteins indicates its role in enhancing pancreatic islet cell functionality.

Pancragen also shows promise in protecting the vascular system, particularly the capillaries, from the damaging effects of elevated glucose levels, which are a common complication of diabetes. This protection could help prevent long-term consequences such as heart disease, kidney disease, and other diabetes-related complications.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://www.peptidesciences.com/pancragen-20mg-bioregulator